102 related articles for article (PubMed ID: 9178645)
1. CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Nakao M; Sata M; Saitsu H; Yutani S; Kawamoto M; Kojiro M; Itoh K
Cell Immunol; 1997 May; 177(2):176-81. PubMed ID: 9178645
[TBL] [Abstract][Full Text] [Related]
2. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
4. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Ormandy LA; Hillemann T; Wedemeyer H; Manns MP; Greten TF; Korangy F
Cancer Res; 2005 Mar; 65(6):2457-64. PubMed ID: 15781662
[TBL] [Abstract][Full Text] [Related]
5. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
[TBL] [Abstract][Full Text] [Related]
6. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ
Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.
Attallah AM; Tabll AA; El-Sadany M; Ibrahim TA; El-Dosoky I
Clin Exp Med; 2003 Nov; 3(3):181-5. PubMed ID: 14648234
[TBL] [Abstract][Full Text] [Related]
8. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
Yin XY; Wang L; Lu MD; Li BJ; Huang JF
Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
[TBL] [Abstract][Full Text] [Related]
9. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
10. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
11. Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells.
Zhang HM; Zhang LW; Ren J; Fan L; Si XM; Liu WC
Cell Immunol; 2006 Feb; 239(2):144-50. PubMed ID: 16814271
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
[TBL] [Abstract][Full Text] [Related]
16. Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PBMC across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in multibacillary patients.
de la Barrera S; Finiasz DM; Fink S; Valdez R; Bottasso O; Balina LM; Sasiain MC
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):45-55. PubMed ID: 9207753
[TBL] [Abstract][Full Text] [Related]
17. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.
Zhang L; Zhang H; Liu W; Wang H; Jia J; Si X; Ren J
Cell Immunol; 2005 Nov; 238(1):61-6. PubMed ID: 16472793
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma.
Zhang HM; Zhang LW; Liu WC; Cheng J; Si XM; Ren J
Cytotherapy; 2006; 8(6):580-8. PubMed ID: 17148035
[TBL] [Abstract][Full Text] [Related]
19. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
